^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MASCT-I

    i
    Other names: MASCT-I, MASCT-1, multiple target antigen stimulating cell therapy, MASCT I
    Associations

    News

    Trials
    Company:
    HRYZ BIOTECH
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. (clinicaltrials.gov)
    P1, N=22, Completed, SYZ Cell Therapy Co..
    New P1 trial • Metastases
    |
    IL10 (Interleukin 10)
    |
    MASCT-I